News & Features

Scientists in Singapore and China validated the test across two patient cohorts, with a sample size of 250 from China and 375 from Singapore, and found it achieved 99.93% specificity and 95–100% sensitivity and differentiated antibody responses to several human coronaviruses.

The researchers found that one in three people with no prior exposure to SARS-CoV-2 nonetheless has T-helper cells capable of recognizing the virus. The likely reason for this is that SARS-CoV-2 shares certain structural similarities with other coronaviruses.

A new study from the Faculty of Health and Medical Sciences at the University of Copenhagen shows that glucagon resistance may be the link between type 2 diabetes and non-alcoholic fatty liver disease.

The company is currently testing whether its engineered antibody or “Humaneered” technology developed over two decades can catapult the company to a leading role in the scramble to conquer COVID-19.

The trial will be conducted at 62 study centers in up to 30,000 adults aged 18 years and older from diverse racial, ethnic, and geographic groups who are healthy, or have stable underlying medical conditions, and including those at increased risk of infection from SARS-CoV-2.

J&J’s Janssen has moved into Phase III with its single-dose COVID-19 vaccine candidate, which it plans to test in up to 60,000 study participants in eight countries, to evaluate its safety and efficacy compared with placebo.

The team, led by Dan Jacobson of the Department of Energy's Oak Ridge National Laboratory, found that genes in the bradykinin system were excessively activated in the lung fluid cells of COVID-19 patients.

The Sanofi-GSK vaccine combines Sanofi’s S-protein COVID-19 antigen, which is based on recombinant DNA technology, and GSK’s pandemic AS03 adjuvant.

AstraZeneca and the University of Oxford resumed the clinical study they paused last week after one U.K. participant developed a “potentially unexplained illness,” while Pfizer and BioNTech have requested FDA approval to add 14,000 participants to their late-stage study.

The study, called the Adaptive COVID-19 Treatment Trial 3 (ACTT 3), is anticipated to enroll more than 1,000 hospitalized adults with COVID-19 at as many as 100 sites in the United States and abroad.